NCT06563635

Brief Summary

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
719

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 31, 2023

Completed
12 months until next milestone

First Posted

Study publicly available on registry

August 21, 2024

Completed
Last Updated

August 21, 2024

Status Verified

August 1, 2024

Enrollment Period

3 months

First QC Date

August 31, 2023

Last Update Submit

August 19, 2024

Conditions

Psoriasis VulgarisTuberculosis

Keywords

psoriasistnf inhibitortuberculosis

Outcome Measures

Primary Outcomes (1)

  • tuberculosis rate

    number of patients with tuberculosis infection after receiving TNF inhibitor therapy

    patients from June 2007 to January 2023, up to 15 years

Study Arms (3)

etanercept

psoriasis patients receiving etanercept therapy

infliximab

psoriasis patients receiving infliximab therapy

adalimumab

psoriasis patients receiving adalimumab therapy

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

psoriasis patients receiving TNF inhibitor therapy in a single center in 15 years

You may qualify if:

  • psoriasis patients receiving TNF inhibitor therapy

You may not qualify if:

  • patients without TNF inhibitor therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bezmialem Vakif University Hospital

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

TuberculosisPsoriasis

Condition Hierarchy (Ancestors)

Mycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 31, 2023

First Posted

August 21, 2024

Study Start

May 1, 2023

Primary Completion

July 31, 2023

Study Completion

July 31, 2023

Last Updated

August 21, 2024

Record last verified: 2024-08

Locations

TU(1)